Published in Cell on May 23, 2023 [1], this paper demonstrates that Membrane Bound O-Acyltransferase Domain Containing 1 (MBOAT1) and Membrane Bound O-Acyltransferase Domain Containing 2 (MBOAT2) can serve as novel targets for cancer treatment, offering new possibilities for treating cancers with specific genetic backgrounds (Fig. 1). This evidence concerns the gene MBOAT2 and cancer.